|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
SG10201708882TA
(en)
|
2013-07-12 |
2017-12-28 |
Ophthotech Corp |
Methods for treating or preventing ophthalmological conditions
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
AU2015231155B2
(en)
*
|
2014-03-21 |
2020-11-12 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
CA2963719A1
(en)
|
2014-11-10 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
Anti-il-1beta antibodies and methods of use
|
|
AU2015345322A1
(en)
*
|
2014-11-10 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-PDGF-B antibodies and methods of use
|
|
KR20170080584A
(ko)
|
2014-11-10 |
2017-07-10 |
에프. 호프만-라 로슈 아게 |
이중특이적 항체 및 안과학에서 이의 사용 방법
|
|
KR20170082594A
(ko)
|
2014-11-10 |
2017-07-14 |
에프. 호프만-라 로슈 아게 |
항-ang2 항체 및 사용 방법
|
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
JP2018506280A
(ja)
*
|
2015-02-06 |
2018-03-08 |
カドモン コーポレイション，リミティド ライアビリティ カンパニー |
免疫調節薬
|
|
WO2016159652A1
(ko)
*
|
2015-03-31 |
2016-10-06 |
일동제약주식회사 |
조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물
|
|
EP3328886B1
(en)
|
2015-07-29 |
2020-09-16 |
Allergan, Inc. |
Heavy chain only antibodies to ang-2
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
WO2017106716A1
(en)
|
2015-12-16 |
2017-06-22 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods of manufacturing protein microparticles
|
|
KR102799807B1
(ko)
|
2015-12-30 |
2025-04-24 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018005904A2
(en)
*
|
2016-07-01 |
2018-01-04 |
Ludwig Institute For Cancer Research Ltd |
Methods and compositions for pdgf-cc inhibition
|
|
CA3031742A1
(en)
|
2016-08-16 |
2018-02-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for quantitating individual antibodies from a mixture
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
CN109021104B
(zh)
*
|
2017-06-12 |
2022-08-12 |
上海睿智化学研究有限公司 |
一种抗人血小板衍生生长因子β受体的抗体及其应用
|
|
CN118878651A
(zh)
|
2017-07-06 |
2024-11-01 |
里珍纳龙药品有限公司 |
用于制备糖蛋白的细胞培养工艺
|
|
KR102711151B1
(ko)
|
2017-12-22 |
2024-10-02 |
리제너론 파마슈티칼스 인코포레이티드 |
약물 제품 불순물 특성화를 위한 시스템 및 방법
|
|
WO2019152303A1
(en)
|
2018-01-31 |
2019-08-08 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for characterizing drug product impurities
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
US12460270B2
(en)
|
2018-02-28 |
2025-11-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
HUE065344T2
(hu)
|
2018-03-19 |
2024-05-28 |
Regeneron Pharma |
Mikrochip kapilláris elektroforézis assay-k és reagensek
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
CN108586611B
(zh)
*
|
2018-04-28 |
2021-01-26 |
暨南大学 |
重组全人源抗破伤风毒素单克隆抗体
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
KR20210052389A
(ko)
|
2018-08-27 |
2021-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
다운스트림 정제에서의 라만 분광법의 사용
|
|
CN112601963B
(zh)
|
2018-08-30 |
2024-05-24 |
瑞泽恩制药公司 |
用于表征蛋白质复合物的方法
|
|
US12098206B2
(en)
|
2018-10-05 |
2024-09-24 |
Seoul National University R&Db Foundation |
PDGF receptor antibody and use thereof
|
|
KR20210114926A
(ko)
|
2019-01-16 |
2021-09-24 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질 내에서 유리 티올을 식별하는 방법
|
|
ES2984072T3
(es)
*
|
2019-03-08 |
2024-10-28 |
Linxis B V |
Moléculas de unión internalizantes que actúan sobre receptores implicados en la proliferación celular o en ladiferenciación celular
|
|
KR20220050087A
(ko)
|
2019-05-03 |
2022-04-22 |
싱가포르 헬스 서비시즈 피티이 엘티디 |
대사성 질환의 치료 및 예방
|
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
|
CA3150234C
(en)
|
2019-09-24 |
2023-12-12 |
Robert Stairs |
Systems and methods for chromatography use and regeneration
|
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
WO2021108548A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
AU2021205893A1
(en)
|
2020-01-08 |
2022-06-23 |
Synthis Therapeutics, Inc. |
ALK5 inhibitor conjugates and uses thereof
|
|
EP4354145B1
(en)
|
2020-01-21 |
2025-09-17 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
CA3170712A1
(en)
*
|
2020-02-07 |
2021-08-12 |
Biorion Technologies B.V. |
Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof.
|
|
AU2021332355A1
(en)
|
2020-08-31 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
EP4214235A1
(en)
*
|
2020-09-16 |
2023-07-26 |
LinXis B.V. |
Internalizing binding molecules
|
|
US12239687B2
(en)
|
2020-11-25 |
2025-03-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
CN116710124A
(zh)
|
2020-12-17 |
2023-09-05 |
瑞泽恩制药公司 |
包封蛋白质的微凝胶的制造
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
AU2022243005A1
(en)
|
2021-03-26 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
AU2022286340A1
(en)
|
2021-06-01 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
WO2023044139A1
(en)
|
2021-09-20 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
IL311245A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
Systems and methods for pH modeling and control
|
|
MX2024004108A
(es)
|
2021-10-07 |
2024-04-19 |
Regeneron Pharma |
Calibracion y correccion de medidor de ph.
|
|
JP2024541952A
(ja)
|
2021-10-26 |
2024-11-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
実験室用水を生成し、実験室用水を異なる温度で分配するためのシステム及び方法
|
|
EP4493921A1
(en)
|
2022-03-18 |
2025-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
US11723955B1
(en)
|
2022-05-13 |
2023-08-15 |
Allgenesis Biotherapeutics Inc. |
VEGFR fusion protein pharmaceutical composition
|
|
US20240198253A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024158880A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
AU2024265540A1
(en)
|
2023-05-01 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
CN118440214B
(zh)
*
|
2024-04-02 |
2025-01-28 |
山东大学 |
一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|